Although expressed at low levels in GBM, HDAC5 can reportedly be transcriptionally activated by nuclear transcription factor Y subunit β (NFYB), suppressing oncogene serine hydroxymethyltransferase 2 (SHMT2), which may reduce glycolysis and TMZ resistance [79]. Here, HDAC5 is linked to glioblastoma.